Liquidia (LQDA) Net Income towards Common Stockholders Growth (1y) (2021 - 2026)
Powered by 
Analysis
Liquidia (LQDA) Net Income towards Common Stockholders Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.43 Bn | 625.67 Bn | 17.26 Bn | -0.05% |
| 2 | AbbVie | 442.46 Bn | 435.89 Bn | 12.70 Bn | 284.27% |
| 3 | Merck | 366.77 Bn | 359.63 Bn | 12.21 Bn | -130.19% |
| 4 | Novartis Ag | 266.59 Bn | 258.90 Bn | 11.24 Bn | -19.23% |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn | -108.13% |
| 6 | Sanofi | 52.40 Bn | 45.02 Bn | 10.79 Bn | -91.06% |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn | 44.59% |
| 9 | United Therapeutics | 21.53 Bn | 18.87 Bn | 683.80 Mn | 7.59% |
| 10 | Liquidia | 6.11 Bn | 5.82 Bn | 160.92 Mn | 279.65% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 279.65% |
| Mar 31, 2026 | 237.78% |
| Dec 31, 2025 | 137.80% |
| Sep 30, 2025 | 88.61% |
| Jun 30, 2025 | -45.04% |
| Mar 31, 2025 | -27.54% |
| Dec 31, 2024 | -40.29% |
| Sep 30, 2024 | -96.52% |
| Jun 30, 2024 | -21.90% |
| Mar 31, 2024 | -218.88% |
| Dec 31, 2023 | -320.17% |
| Sep 30, 2023 | -73.67% |
| Jun 30, 2023 | -148.94% |
| Mar 31, 2023 | 36.88% |
| Dec 31, 2022 | 43.50% |
| Sep 30, 2022 | -24.87% |
| Jun 30, 2022 | -44.18% |
| Mar 31, 2022 | -63.70% |
| Dec 31, 2021 | 28.12% |
| Sep 30, 2021 | 51.36% |